ARDX vs BMRN · rev $215.3M vs P/E 40, rev $1.76B
Ardelyx Inc (ARDX) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
Ardelyx Inc (ARDX) is a biotechnology company listed on US.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Latest reported ARDX revenue for 2026-06-30 was $215.3M. Net income was -$54.3M. ARDX currently screens at market cap $1.37B.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
ARDX currently screens at market cap $1.37B. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the ARDX and BMRN stock pages for the full models.
Not investment advice.